PE20211280A1 - Sales cristalinas de un inhibidor de calicreina plasmatica - Google Patents

Sales cristalinas de un inhibidor de calicreina plasmatica

Info

Publication number
PE20211280A1
PE20211280A1 PE2021000587A PE2021000587A PE20211280A1 PE 20211280 A1 PE20211280 A1 PE 20211280A1 PE 2021000587 A PE2021000587 A PE 2021000587A PE 2021000587 A PE2021000587 A PE 2021000587A PE 20211280 A1 PE20211280 A1 PE 20211280A1
Authority
PE
Peru
Prior art keywords
alkyl
hydrogen
plasmatic
crystalline salts
delivery system
Prior art date
Application number
PE2021000587A
Other languages
English (en)
Spanish (es)
Inventor
Yahya El-Kattan
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70457981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20211280(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of PE20211280A1 publication Critical patent/PE20211280A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PE2021000587A 2018-11-02 2019-11-01 Sales cristalinas de un inhibidor de calicreina plasmatica PE20211280A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862754983P 2018-11-02 2018-11-02
PCT/US2019/059385 WO2020092898A1 (en) 2018-11-02 2019-11-01 Crystalline salts of a plasma kallikrein inhibitor

Publications (1)

Publication Number Publication Date
PE20211280A1 true PE20211280A1 (es) 2021-07-19

Family

ID=70457981

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000587A PE20211280A1 (es) 2018-11-02 2019-11-01 Sales cristalinas de un inhibidor de calicreina plasmatica

Country Status (22)

Country Link
US (11) US10662160B1 (cg-RX-API-DMAC7.html)
EP (1) EP3873463A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022505670A (cg-RX-API-DMAC7.html)
KR (1) KR102810837B1 (cg-RX-API-DMAC7.html)
CN (1) CN112969458A (cg-RX-API-DMAC7.html)
AR (1) AR116951A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019374115B8 (cg-RX-API-DMAC7.html)
BR (1) BR112021008249A2 (cg-RX-API-DMAC7.html)
CA (1) CA3117123A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001094A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007172A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191192A1 (cg-RX-API-DMAC7.html)
IL (2) IL322896A (cg-RX-API-DMAC7.html)
MA (1) MA54087A (cg-RX-API-DMAC7.html)
MX (1) MX2021004917A (cg-RX-API-DMAC7.html)
PE (1) PE20211280A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550883A1 (cg-RX-API-DMAC7.html)
PY (1) PY1991831A (cg-RX-API-DMAC7.html)
SG (1) SG11202103804TA (cg-RX-API-DMAC7.html)
TW (1) TW202031255A (cg-RX-API-DMAC7.html)
UY (1) UY38438A (cg-RX-API-DMAC7.html)
WO (1) WO2020092898A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221373T1 (hr) 2014-03-07 2023-01-06 Biocryst Pharmaceuticals, Inc. Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
WO2021025969A1 (en) * 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Solid state forms of berotralstat
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
EP1828187A2 (en) 2004-12-15 2007-09-05 Brystol-Myers Squibb Company Crystalline forms of a factor xa inhibitor
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
CN102892763B (zh) * 2010-05-19 2016-03-09 桑多斯股份公司 泊沙康唑及泊沙康唑中间体的纯化
JP5808818B2 (ja) 2010-11-25 2015-11-10 ラツィオファーム・ゲーエムベーハー アファチニブの新規塩及び多形形態
GB201212081D0 (en) * 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
HRP20221373T1 (hr) * 2014-03-07 2023-01-06 Biocryst Pharmaceuticals, Inc. Supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi
FI4019022T3 (fi) 2015-10-01 2024-04-19 Biocryst Pharm Inc Ihmisen plasman kallikreiinin estäjiä
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
EP4010320A4 (en) 2019-08-06 2023-08-16 Biocryst Pharmaceuticals, Inc. Process-scale synthesis of a plasma kallikrein inhibitor

Also Published As

Publication number Publication date
US12552750B2 (en) 2026-02-17
US11618733B2 (en) 2023-04-04
BR112021008249A2 (pt) 2021-08-03
MX2021004917A (es) 2021-06-18
KR102810837B1 (ko) 2025-05-20
TW202031255A (zh) 2020-09-01
US12545647B2 (en) 2026-02-10
IL282454A (en) 2021-06-30
US20220204454A1 (en) 2022-06-30
AU2019374115A1 (en) 2021-06-03
US20250388549A1 (en) 2025-12-25
CL2021001094A1 (es) 2021-10-15
JP2024109860A (ja) 2024-08-14
AU2019374115B1 (en) 2025-07-17
US20250388545A1 (en) 2025-12-25
US12545646B2 (en) 2026-02-10
US20240109844A1 (en) 2024-04-04
US10662160B1 (en) 2020-05-26
UY38438A (es) 2020-05-29
CO2021007172A2 (es) 2021-06-10
US20250388547A1 (en) 2025-12-25
US20250376447A1 (en) 2025-12-11
EP3873463A4 (en) 2022-06-22
KR20210087037A (ko) 2021-07-09
IL322896A (en) 2025-10-01
SG11202103804TA (en) 2021-05-28
US20250376448A1 (en) 2025-12-11
EA202191192A1 (ru) 2021-09-23
US11117867B2 (en) 2021-09-14
EP3873463A1 (en) 2021-09-08
US12590068B2 (en) 2026-03-31
US20200140389A1 (en) 2020-05-07
WO2020092898A1 (en) 2020-05-07
MA54087A (fr) 2022-02-09
US12344585B2 (en) 2025-07-01
US20250388546A1 (en) 2025-12-25
CA3117123A1 (en) 2020-05-07
US20250388548A1 (en) 2025-12-25
PY1991831A (es) 2020-07-03
JP2022505670A (ja) 2022-01-14
US20200308118A1 (en) 2020-10-01
CN112969458A (zh) 2021-06-15
AR116951A1 (es) 2021-06-30
US12590069B2 (en) 2026-03-31
US12545645B2 (en) 2026-02-10
PH12021550883A1 (en) 2022-02-21
AU2019374115B8 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
PE20191837A1 (es) Sistema de administracion de liberacion sostenida que comprenden ligantes que no dejan huellas
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
HN2012001037A (es) Derivados del acido carbamoil-metil-amino-acetico sustiituido como inhibidores de nep novedosos
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
AR049647A1 (es) Cis-imidazolinas
PE20080093A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
CO6270307A2 (es) Derivados bis-(sulfonilamino) en terapia
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
PE20211646A1 (es) Administracion sostenida de polipeptidos similares a la angiopoyetina 3
AR061419A1 (es) Compuestos de piridil amida sustituidos como moduladores del receptor de histamida h3
PE20240930A1 (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
CL2019000768A1 (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos.
CU20210023A7 (es) Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4
PY2228191A (es) Nuevos derivados de heteroaril aminopropanol
CY1111102T1 (el) 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv
PE20190106A1 (es) Inhibidores del potenciador del homologo zeste 2
CL2023000418A1 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CL2020001277A1 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2.
CO2019002616A2 (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
AR051315A1 (es) Pirimidinas 5-sustituidas inhibidoras del vih
DOP2023000205A (es) Nuevos moduladores de nr2b alostéricos negativos de ciclopenta[c]pirrol
PE20040943A1 (es) 2-AMINOIMIDAZOLES SUSTITUIDOS COMO INHIBIDORES DEL INTERCAMBIADOR Na/H SUBTIPO 3 (NHE 3)
AR085822A1 (es) Moduladores alostericos positivos del receptor nicotinico de acetilcolina
UY39722A (es) Nuevos derivados de heteroaril aminopropanol